This research explores the molecular origins and progression of medulloblastoma, a highly aggressive pediatric brain cancer. While sequencing has defined four major molecular subgroups, current treatments fail to eliminate the stem and progenitor cells that drive tumor growth and drug resistance. The authors argue for the development of faithful human models, such as 3D organoids, to better mirror human-specific brain development compared to traditional mouse models. A significant focus is placed on the post-transcriptional landscape, suggesting that mechanisms like alternative splicing offer untapped opportunities for targeted therapies and biomarkers. Furthermore, the text addresses the critical need to understand metastatic spread, which remains the leading cause of mortality in these young patients. Ultimately, the sources advocate for shifting beyond data collection toward functional validation of oncogenic drivers to improve clinical outcomes.

References:

• Zagozewski J, Haldipur P, Millen K J, et al. Medulloblastoma stem cell programs: Molecular roadmaps of disease progression[J]. Developmental Cell, 2025.